Neglected Comorbidity of Chronic Heart Failure: Iron Deficiency
Iron deficiency is a significant comorbidity of heart failure (HF), defined as the inability of...
Read More
Author: Rebecca Shover
Incidence, Treatment and Clinical Impact of Iron Deficiency in Chronic Heart Failure: A Longitudinal Analysis
In patients with heart failure (HF), iron deficiency (ID) is a well-recognized therapeutic target;...
Read More
Healthier Without You
“I would be a lot healthier if you’d stop finding things wrong with...
Read More
COVID-19 Vaccination During Pregnancy Benefits Neonates and Pregnant Individuals
Findings that show COVID-19 vaccination during pregnancy improves neonatal outcomes can serve “a...
Read More
Assessing the Burden of RSV in Children & Adults
RSV was associated with significant morbidity among children and adults, and clinicians ‘should...
Read More
Head or Tails
“Heads, fat is bad and carbs are good. Tails, fat is good and carbs are...
Read More
Factors Associated With Improved COVID-19 Outcomes for CLL
Patients with chronic lymphocytic leukemia (CLL) infected with COVID-19 during the most recent...
Read More
Test Your ACR Knowledge!
The ACR 2022 PhysQuiz was created by the editorial staff at Physician’s...
Read More
Butter is OK
“The good news, it’s OK to eat butter after all. The bad news, it’s not OK to...
Read More
Baseline CTC Count Can Guide First-Line Treatment in HR-Positive/HER-Negative Metastatic Breast Cancer
A single assessment of the circulating tumor cells (CTC) count before treatment can guide the...
Read More
Resistance to CDK4/6 Inhibitors Likely Due to Expansion of Pre-Existing Resistant Clones
In vitro studies using DNA barcoded cell lines demonstrated that resistance to CDK4/6 inhibitors...
Read More
No Benefit of Palbociclib With Fulvestrant Beyond Progression on Prior CDK4/6 Inhibition
Among patients with HR-positive/HER2-negative metastatic breast cancer, combining palbociclib with...
Read More
Improved Benefit of Elacestrant With Longer Duration of CDK4/6 Inhibition
Duration of first-line CDK4/6 inhibitor therapy in patients with ER-positive/HER2-negative...
Read More
T-DXd Superior Vs Chemotherapy-Based Treatments When Previously Treated With T-DM1
Compared with capecitabine-based regimens, trastuzumab deruxtecan (T-DXd) led to higher response...
Read More
Germline Pathogenic Variants for Breast Cancer Also Increase Contralateral Breast Cancer Risk
In women carrying a germline pathogenic variant for breast cancer, like BRCA1, BRCA2, or CHEK2,...
Read More
Anti-PD-1/Anti-LAG-3 Combination Highly Effective in HER2-Negative Breast Cancer
Paclitaxel/cemiplimab/fianlimab is a highly effective combination for neoadjuvant therapy in both...
Read More
Endocrine Interruption Does Not Impact Short-Term Disease in Breast Cancer
Patients with breast cancer who pause their endocrine therapy to try to get pregnant experienced...
Read More
MammaPrint Predicts Extended Endocrine Therapy Benefit
In addition to predicting the benefit of adjuvant chemotherapy in patients with early breast...
Read More